Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease

Abstract

Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5′-GCCCAAGCTGGCATCCGTCA-3′, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.

Description

RELATED APPLICATIONS[0001]This application is related to and claims priority to two US Provisional Patent Application: 60 / 632,826 filed on Dec. 2, 2004, and US Provisional Patent Application 60 / 716,355 filed on Sept. 12, 2005. Both of which are incorporated herein in their entirety.SEQUENCE LISTING[0002]A sequence listing is filed with this application under 37 CFR 1.821 and is hereby incorporated by reference.FIELD OF THE INVENTION[0003]This invention relates to antisense oligonucleotide therapeutic compound to modulate the expression of intracellular adhesion molecule-1 (ICAM-1) for the amelioration and / or treatment of inflammatory bowel diseases including Crohn's disease, ulcerative colitis and pouchitis.BACKGROUND OF THE INVENTION[0004]ICAM-1, a member of the immunoglobulin (Ig) superfamily, is an inducible transmembrane glycoprotein constitutively expressed at low levels on vascular endothelial cells and on a subset of leucocytes (Dustin et al., J. Immunol., 137:245-54, 1986; R...

AI Technical Summary

Benefits of technology

[0035]Disclosed is the use of composition comprising an antisense oligonucleotide compound 8 to 80 nucleobases in length wherein the oligonucleotide comprises at least an 8 nucleobase portion that specifically hybridizes with nucleotides 2114 to 2133 of SEQ ID NO: 1 for the preparation of a medicament for rectal administration to an individual to promote mucosal healing and a durable response in an individual suffering from ulcerative colitis. A further use for the medicament is to produce disease modifying outcomes. These uses can be accomplished with minimal systemic exposure to the active components of the composition and without substantial undesirable side effects. It is further disclosed that the oligonucleotide can have the sequence of SEQ ID NO: 2, and that the medicament for rectal administration can be prepared using hydroxypropyl methylcellulose. In a preferred embodiment, the composition is used for the manufacture of a medicament for the treatment of individuals having moderate to severe ulcerative colitis.

Problems solved by technology

In the absence of invasive imaging studies, it is not possible to distinguish the two diseases which are often considered as a single disease in a number of publications and studies.

However, ulcerative colitis may be a single event, or continuous with unrelenting symptoms.

Although there are many choices for therapeutic interventions in IBD, many have undesirable side effects that make them less than ideal for treatment of chronic disease.

Although commonly used for maintenance therapy, 5-ASAs have not been demonstrated to be effective in maintaining remission.

Mesalamine, olsalazine and balsalazide which do not contain sulfa groups result in substantially fewer side effects, but still can cause rash, headaches and fever.

The use of corticosteroids is limited by the number of severe and significant side effects associated with their use.

Common side effects of short term use include insomnia, night sweats, mood changes and altered glucose metabolism.

Prolonged therapy can lead to adrenal atrophy, whereas abrupt cessation can cause adrenal insufficiency, hypotension, and even death.

Other side effects include acne, abnormal fat deposition, excessive hair growth and osteoporosis.

However, some physicians provide no pharmacological interventions during periods of remission.

Immunosuppressant interventions are not without undesirable side effects.

As with all of the other therapies, there are side effects of long term treatment with antibiotics.

However, as it is a biological agent, an immune response can limit utility of the drug.

As with all other therapies for IBD, there are substantial side effects of infliximab.

However, removal of larger or multiple segments of the intestine can result in short bowel syndrome in which individuals are unable to absorb nutrients.

Removal of portions of the large intestine can result in the need for colostomy or other further surgical procedures.

Therefore, surgery is not a preferred method of treatment of IBD.

Surgical interventions for the treatment of IBD can result in further disease.

Despite a number of possible interventions for the treatment of IBD, none of them are fully satisfactory due to limited efficacy, undesirable side effects or both.